Literature DB >> 28133811

Complex immune correlates of protection in HIV-1 vaccine efficacy trials.

Georgia D Tomaras1, Stanley A Plotkin2,3.   

Abstract

Development of an efficacious HIV-1 vaccine is a major priority for improving human health worldwide. Vaccine-mediated protection against human pathogens can be achieved through elicitation of protective innate, humoral, and cellular responses. Identification of specific immune responses responsible for pathogen protection enables vaccine development and provides insights into host defenses against pathogens and the immunological mechanisms that most effectively fight infection. Defining immunological correlates of transmission risk in preclinical and clinical HIV-1 vaccine trials has moved the HIV-1 vaccine development field forward and directed new candidate vaccine development. Immune correlate studies are providing novel hypotheses about immunological mechanisms that may be responsible for preventing HIV-1 acquisition. Recent results from HIV-1 immune correlates work has demonstrated that there are multiple types of immune responses that together, comprise an immune correlate-thus implicating polyfunctional immune control of HIV-1 transmission. An in depth understanding of these complex immunological mechanisms of protection against HIV-1 will accelerate the development of an efficacious HIV-1 vaccine.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990HIVzzm321990; antibodies; cellular; complex immune correlate; correlate of decreased HIV-1 risk; correlates of protection; humoral; immunity; sieve analysis; vaccination

Mesh:

Substances:

Year:  2017        PMID: 28133811      PMCID: PMC5330182          DOI: 10.1111/imr.12514

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  158 in total

1.  Duration of humoral immunity to common viral and vaccine antigens.

Authors:  Ian J Amanna; Nichole E Carlson; Mark K Slifka
Journal:  N Engl J Med       Date:  2007-11-08       Impact factor: 91.245

Review 2.  Difficulties in establishing a serological correlate of protection after immunization with Haemophilus influenzae conjugate vaccines.

Authors:  H Käyhty
Journal:  Biologicals       Date:  1994-12       Impact factor: 1.856

3.  Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys.

Authors:  Peter Abbink; Rafael A Larocca; Rafael A De La Barrera; Christine A Bricault; Edward T Moseley; Michael Boyd; Marinela Kirilova; Zhenfeng Li; David Ng'ang'a; Ovini Nanayakkara; Ramya Nityanandam; Noe B Mercado; Erica N Borducchi; Arshi Agarwal; Amanda L Brinkman; Crystal Cabral; Abishek Chandrashekar; Patricia B Giglio; David Jetton; Jessica Jimenez; Benjamin C Lee; Shanell Mojta; Katherine Molloy; Mayuri Shetty; George H Neubauer; Kathryn E Stephenson; Jean Pierre S Peron; Paolo M de A Zanotto; Johnathan Misamore; Brad Finneyfrock; Mark G Lewis; Galit Alter; Kayvon Modjarrad; Richard G Jarman; Kenneth H Eckels; Nelson L Michael; Stephen J Thomas; Dan H Barouch
Journal:  Science       Date:  2016-08-04       Impact factor: 47.728

4.  Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2.

Authors:  Hua-Xin Liao; Mattia Bonsignori; S Munir Alam; Jason S McLellan; Georgia D Tomaras; M Anthony Moody; Daniel M Kozink; Kwan-Ki Hwang; Xi Chen; Chun-Yen Tsao; Pinghuang Liu; Xiaozhi Lu; Robert J Parks; David C Montefiori; Guido Ferrari; Justin Pollara; Mangala Rao; Kristina K Peachman; Sampa Santra; Norman L Letvin; Nicos Karasavvas; Zhi-Yong Yang; Kaifan Dai; Marie Pancera; Jason Gorman; Kevin Wiehe; Nathan I Nicely; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Jaranit Kaewkungwal; Punnee Pitisuttithum; James Tartaglia; Faruk Sinangil; Jerome H Kim; Nelson L Michael; Thomas B Kepler; Peter D Kwong; John R Mascola; Gary J Nabel; Abraham Pinter; Susan Zolla-Pazner; Barton F Haynes
Journal:  Immunity       Date:  2013-01-11       Impact factor: 31.745

5.  Does participation in an HIV vaccine efficacy trial affect risk behaviour in South Africa?

Authors:  G E Gray; B Metch; G Churchyard; K Mlisana; M Nchabeleng; M Allen; Z Moodie; J Kublin; L-G Bekker
Journal:  Vaccine       Date:  2013-01-29       Impact factor: 3.641

6.  A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants.

Authors:  Selidji Todagbe Agnandji; Bertrand Lell; José Francisco Fernandes; Béatrice Peggy Abossolo; Barbara Gaelle Nfono Ondo Methogo; Anita Lumeka Kabwende; Ayola Akim Adegnika; Benjamin Mordmüller; Saadou Issifou; Peter Gottfried Kremsner; Jahit Sacarlal; Pedro Aide; Miguel Lanaspa; John J Aponte; Sonia Machevo; Sozinho Acacio; Helder Bulo; Betuel Sigauque; Eusébio Macete; Pedro Alonso; Salim Abdulla; Nahya Salim; Rose Minja; Maxmillian Mpina; Saumu Ahmed; Ali Mohammed Ali; Ali Takadir Mtoro; Ali Said Hamad; Paul Mutani; Marcel Tanner; Halidou Tinto; Umberto D'Alessandro; Hermann Sorgho; Innocent Valea; Biébo Bihoun; Issa Guiraud; Berenger Kaboré; Olivier Sombié; Robert Tinga Guiguemdé; Jean Bosco Ouédraogo; Mary J Hamel; Simon Kariuki; Martina Oneko; Chris Odero; Kephas Otieno; Norbert Awino; Meredith McMorrow; Vincent Muturi-Kioi; Kayla F Laserson; Laurence Slutsker; Walter Otieno; Lucas Otieno; Nekoye Otsyula; Stacey Gondi; Allan Otieno; Victorine Owira; Esther Oguk; George Odongo; Jon Ben Woods; Bernhards Ogutu; Patricia Njuguna; Roma Chilengi; Pauline Akoo; Christine Kerubo; Charity Maingi; Trudie Lang; Ally Olotu; Philip Bejon; Kevin Marsh; Gabriel Mwambingu; Seth Owusu-Agyei; Kwaku Poku Asante; Kingsley Osei-Kwakye; Owusu Boahen; David Dosoo; Isaac Asante; George Adjei; Evans Kwara; Daniel Chandramohan; Brian Greenwood; John Lusingu; Samwel Gesase; Anangisye Malabeja; Omari Abdul; Coline Mahende; Edwin Liheluka; Lincoln Malle; Martha Lemnge; Thor G Theander; Chris Drakeley; Daniel Ansong; Tsiri Agbenyega; Samuel Adjei; Harry Owusu Boateng; Theresa Rettig; John Bawa; Justice Sylverken; David Sambian; Anima Sarfo; Alex Agyekum; Francis Martinson; Irving Hoffman; Tisungane Mvalo; Portia Kamthunzi; Rutendo Nkomo; Tapiwa Tembo; Gerald Tegha; Mercy Tsidya; Jane Kilembe; Chimwemwe Chawinga; W Ripley Ballou; Joe Cohen; Yolanda Guerra; Erik Jongert; Didier Lapierre; Amanda Leach; Marc Lievens; Opokua Ofori-Anyinam; Aurélie Olivier; Johan Vekemans; Terrell Carter; David Kaslow; Didier Leboulleux; Christian Loucq; Afiya Radford; Barbara Savarese; David Schellenberg; Marla Sillman; Preeti Vansadia
Journal:  N Engl J Med       Date:  2012-11-09       Impact factor: 91.245

7.  Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines.

Authors:  Amy W Chung; Musie Ghebremichael; Hannah Robinson; Eric Brown; Ickwon Choi; Sophie Lane; Anne-Sophie Dugast; Matthew K Schoen; Morgane Rolland; Todd J Suscovich; Alison E Mahan; Larry Liao; Hendrik Streeck; Charla Andrews; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Mark S de Souza; Jaranit Kaewkungwal; Punnee Pitisuttithum; Donald Francis; Nelson L Michael; Jerome H Kim; Chris Bailey-Kellogg; Margaret E Ackerman; Galit Alter
Journal:  Sci Transl Med       Date:  2014-03-19       Impact factor: 17.956

8.  Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination.

Authors:  Nicole L Yates; Hua-Xin Liao; Youyi Fong; Allan deCamp; Nathan A Vandergrift; William T Williams; S Munir Alam; Guido Ferrari; Zhi-yong Yang; Kelly E Seaton; Phillip W Berman; Michael D Alpert; David T Evans; Robert J O'Connell; Donald Francis; Faruk Sinangil; Carter Lee; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Jaranit Kaewkungwal; Punnee Pitisuttithum; James Tartaglia; Abraham Pinter; Susan Zolla-Pazner; Peter B Gilbert; Gary J Nabel; Nelson L Michael; Jerome H Kim; David C Montefiori; Barton F Haynes; Georgia D Tomaras
Journal:  Sci Transl Med       Date:  2014-03-19       Impact factor: 17.956

9.  Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial.

Authors:  Morgane Rolland; Sodsai Tovanabutra; Allan C deCamp; Nicole Frahm; Peter B Gilbert; Eric Sanders-Buell; Laura Heath; Craig A Magaret; Meera Bose; Andrea Bradfield; Annemarie O'Sullivan; Jacqueline Crossler; Teresa Jones; Marty Nau; Kim Wong; Hong Zhao; Dana N Raugi; Stephanie Sorensen; Julia N Stoddard; Brandon S Maust; Wenjie Deng; John Hural; Sheri Dubey; Nelson L Michael; John Shiver; Lawrence Corey; Fusheng Li; Steve G Self; Jerome Kim; Susan Buchbinder; Danilo R Casimiro; Michael N Robertson; Ann Duerr; M Juliana McElrath; Francine E McCutchan; James I Mullins
Journal:  Nat Med       Date:  2011-02-27       Impact factor: 53.440

10.  High levels of IgG3 anti ICB2-5 in Plasmodium vivax-infected individuals who did not develop symptoms.

Authors:  Fernanda G Versiani; Maria E M Almeida; Gisely C Melo; Francivaldo O L Versiani; Patrícia P Orlandi; Luís André M Mariúba; Leidiane A Soares; Luciana P Souza; Antonio A da Silva Balieiro; Wuelton M Monteiro; Fabio T M Costa; Hernando A del Portillo; Marcus V G Lacerda; Paulo A Nogueira
Journal:  Malar J       Date:  2013-08-27       Impact factor: 2.979

View more
  62 in total

Review 1.  Principles of Broad and Potent Antiviral Human Antibodies: Insights for Vaccine Design.

Authors:  James E Crowe
Journal:  Cell Host Microbe       Date:  2017-08-09       Impact factor: 21.023

2.  Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.

Authors:  Benedikt Asbach; Karen V Kibler; Josef Köstler; Beatriz Perdiguero; Nicole L Yates; Sherry Stanfield-Oakley; Georgia D Tomaras; Shing-Fen Kao; Kathryn E Foulds; Mario Roederer; Michael S Seaman; David C Montefiori; Robert Parks; Guido Ferrari; Donald N Forthal; Sanjay Phogat; James Tartaglia; Susan W Barnett; Steven G Self; Raphael Gottardo; Anthony D Cristillo; Deborah E Weiss; Lindsey Galmin; Song Ding; Jonathan L Heeney; Mariano Esteban; Bertram L Jacobs; Giuseppe Pantaleo; Ralf Wagner
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

3.  Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa.

Authors:  Glenda E Gray; Ying Huang; Nicole Grunenberg; Fatima Laher; Surita Roux; Erica Andersen-Nissen; Stephen C De Rosa; Britta Flach; April K Randhawa; Ryan Jensen; Edith M Swann; Linda-Gail Bekker; Craig Innes; Erica Lazarus; Lynn Morris; Nonhlanhla N Mkhize; Guido Ferrari; David C Montefiori; Xiaoying Shen; Sheetal Sawant; Nicole Yates; John Hural; Abby Isaacs; Sanjay Phogat; Carlos A DiazGranados; Carter Lee; Faruk Sinangil; Nelson L Michael; Merlin L Robb; James G Kublin; Peter B Gilbert; M Juliana McElrath; Georgia D Tomaras; Lawrence Corey
Journal:  Sci Transl Med       Date:  2019-09-18       Impact factor: 17.956

4.  Intragastric Administration of Lactobacillus plantarum and 2,2'-Dithiodipyridine-Inactivated Simian Immunodeficiency Virus (SIV) Does Not Protect Indian Rhesus Macaques from Intrarectal SIV Challenge or Reduce Virus Replication after Transmission.

Authors:  Diane G Carnathan; Joseph J Mackel; Shelby L Sweat; Chiamaka A Enemuo; Etse H Gebru; Pallavi Dhadvai; Sailaja Gangadhara; Sakeenah Hicks; Thomas H Vanderford; Rama R Amara; José Esparza; Wei Lu; Jean-Marie Andrieu; Guido Silvestri
Journal:  J Virol       Date:  2018-04-27       Impact factor: 5.103

Review 5.  Distinguishing Causation From Correlation in the Use of Correlates of Protection to Evaluate and Develop Influenza Vaccines.

Authors:  Wey Wen Lim; Nancy H L Leung; Sheena G Sullivan; Eric J Tchetgen Tchetgen; Benjamin J Cowling
Journal:  Am J Epidemiol       Date:  2020-03-02       Impact factor: 4.897

6.  Striking a balance in an antibody network: A roadmap for HIV-1 vaccines.

Authors:  Tysheena P Charles; Cynthia A Derdeyn
Journal:  J Clin Invest       Date:  2019-11-01       Impact factor: 14.808

7.  The quest for an antibody-based HIV vaccine.

Authors:  Barton F Haynes; John R Mascola
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

Review 8.  Systems serology for decoding infection and vaccine-induced antibody responses to HIV-1.

Authors:  Srivamshi Pittala; Kyle S Morrison; Margaret E Ackerman
Journal:  Curr Opin HIV AIDS       Date:  2019-07       Impact factor: 4.283

9.  Vaccine targeting SIVmac251 protease cleavage sites protects macaques against vaginal infection.

Authors:  Hongzhao Li; Robert W Omange; Binhua Liang; Nikki Toledo; Yan Hai; Lewis R Liu; Dane Schalk; Jose Crecente-Campo; Tamara G Dacoba; Andrew B Lambe; So-Yon Lim; Lin Li; Mohammad Abul Kashem; Yanmin Wan; Jorge F Correia-Pinto; Michael S Seaman; Xiao Qing Liu; Robert F Balshaw; Qingsheng Li; Nancy Schultz-Darken; Maria J Alonso; Francis A Plummer; James B Whitney; Ma Luo
Journal:  J Clin Invest       Date:  2020-12-01       Impact factor: 14.808

Review 10.  Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field.

Authors:  Prasad S Kulkarni; Julia L Hurwitz; Eric A F Simões; Pedro A Piedra
Journal:  Viral Immunol       Date:  2018-01-16       Impact factor: 2.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.